For research use only. Not for therapeutic Use.
IMB-301 is a specific HIV-1 replication inhibitor that binds to hA3G (human APOBEC3G), interrupts the hA3G-Vif interaction and inhibits Vif-mediated degradation of hA3G. IMB-301 inhibits the replication of HIV-1 in H9 cells (IC50=8.63 uM). Human APOBEC3G is a restriction factor that inhibits human immunodeficiency 1 virus (HIV-1) replication[1].
IMB-301 is able to increase virion encapsidation of hA3G via its ability to impair the degradation of hA3Gby Vif, which results in hA3G-dependent anti-HIV activity. IMB-301 binds to hA3G, restores hA3G expression in the presence of Vif, and inhibits the replication of HIV-1 in a hA3G-dependent manner[1].
| Catalog Number | I045527 |
| CAS Number | 64009-84-3 |
| Synonyms | 1-[2-(2,4-dichlorophenyl)-4-(4-fluorophenoxy)butyl]imidazole |
| Molecular Formula | C19H17Cl2FN2O |
| Purity | ≥95% |
| InChI | InChI=1S/C19H17Cl2FN2O/c20-15-1-6-18(19(21)11-15)14(12-24-9-8-23-13-24)7-10-25-17-4-2-16(22)3-5-17/h1-6,8-9,11,13-14H,7,10,12H2 |
| InChIKey | FHKXBOJPHOEMQO-UHFFFAOYSA-N |
| SMILES | C1=CC(=CC=C1OCCC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)F |
| Reference | [1]. Ma L, et al. Identification of small molecule compounds targeting the interaction of HIV-1 Vif and human APOBEC3G by virtual screening and biological evaluation. Sci Rep. 2018;8(1):8067. Published 2018 May 23. |
